Supernus Pharmaceuticals
SUPN
#4496
Rank
NZ$4.39 B
Marketcap
NZ$75.71
Share price
-2.15%
Change (1 day)
20.85%
Change (1 year)

Earnings for Supernus Pharmaceuticals (SUPN)

Earnings in 2026 (TTM): -NZ$91.46 Million

According to Supernus Pharmaceuticals 's latest financial reports the company's current earnings are NZ$0.77 Billion. In 2025 the company made an earning of -NZ$83.17 Million a decrease over its 2024 earnings that were of NZ$0.13 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Supernus Pharmaceuticals from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -NZ$91.46 Million9.96%
2025 -NZ$83.17 Million-161.15%
2024 NZ$0.13 B1446.62%
2023 NZ$8.79 M-92.36%
2022 NZ$0.11 B-29.8%
2021 NZ$0.16 B-49.79%
2020 NZ$0.32 B12.99%
2019 NZ$0.28 B7.58%
2018 NZ$0.26 B54.9%
2017 NZ$0.17 B84.25%
2016 NZ$94.07 M202.27%
2015 NZ$31.12 M-462.04%
2014 -NZ$8.6 Million-94%
2013 -NZ$0.15 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
NZ$44.06 B-49,701.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
NZ$13.80 B-15,636.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$52.79 B-59,527.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$16.27 B-18,423.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Zogenix
ZGNX
-NZ$0.36 Billion 304.83%๐Ÿ‡บ๐Ÿ‡ธ USA
United Therapeutics
UTHR
NZ$2.75 B-3,202.82%๐Ÿ‡บ๐Ÿ‡ธ USA